Evidence map›Paper›PMID 38647194›Full record

SynthesisJournal of Crohn's & colitis2024

Work Productivity Impairment in Persons with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.

Michael Youssef, Nariman Hossein-Javaheri, Tedi Hoxha, Christina Mallouk, Parul Tandon

Registry-linked trialAbstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in Journal of Crohn's & colitis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07237516 (Zymfentra), which is not on this map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07237516 recruitingnot on this mapstarted 2025, after this paper: background citation

Zymfentra (Infliximab-dyyb) REal World Cohort STudy

Typeobservational_patient_registrySponsorUniversity of North Carolina, Chapel HillRan2025 to 2028Enrolled200ConditionsUlcerative Colitis (UC), Crohn's Disease (CD), Indeterminate Colitis, Inflammatory Bowel Disease (IBD)
3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Regulation ofFrontiers in immunology · 2024
    Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Michael YoussefDepartment of Internal Medicine, University of Toronto, Toronto, ON, Canada.ORCID 0000-0001-8463-6601
Nariman Hossein-JavaheriDepartment of Internal Medicine, University at Buffalo, Buffalo, NY, USA.
Tedi HoxhaDepartment of Internal Medicine, University of Toronto, Toronto, ON, Canada.ORCID 0009-0009-6208-6237
Christina MalloukFaculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
Parul TandonDivision of Gastroenterology and Hepatology, University Health Network, University of Toronto, Toronto, ON, Canada.ORCID 0000-0003-0021-2161

Funding

Mount Sinai Resident Research Funding
6 · The paper itself

Abstract

BACKGROUND AND

aimsThe impact of inflammatory bowel disease [IBD] on work productivity remains unclear. In this systematic review and meta-analysis, we quantify work-related outcomes and employment data among persons with IBD.

methodsA systematic literature search was conducted in MEDLINE, EMBASE, the Cochrane library, Scopus, ProQuest, and clinicaltrials.gov from inception to February 2023, to identify studies on work productivity in persons with IBD aged > 18 years. Work productivity was defined primarily by the Work Productivity and Activity Impairment [WPAI] questionnaire which includes absenteeism, presenteeism, overall work impairment, and non-work activity impairment. In addition, we included data on employment, sick leaves, disability pensions, and indirect costs due to productivity loss. Pooled effect analysis was conducted using a random-effects model for pooled estimates of continuous and proportional data with 95% confidence intervals.

resultsAmong all patients with IBD, the pooled estimates were 16.4% for absenteeism, 35.9% for presenteeism, 39.4% for overall work impairment, and 46.0% for non-work activity impairment. Indirect costs from overall work impairment were 5131.09 euros/patient/year. Only two-thirds of IBD patients were employed, and one in three lost their jobs due to IBD. Among those employed, 39.5% report sick days, 21.3% report work disability, and 12.3% receive disability pensions. Most studies demonstrate clinically meaningful improvements in work productivity with medical and/or surgical therapies.

conclusionPersons with IBD experience significant work impairment and associated indirect costs. This highlights the need for appropriate workplace accommodations and timely medical therapy to alleviate the burden of disease and improve work outcomes.

Indexed as

AbsenteeismEfficiencyEmploymentInflammatory Bowel DiseasesCost of IllnessHumansPresenteeismSick LeaveInflammatory bowel diseasework productivityWPAI

Identifiers

PMID38647194
PMCPMC11369077

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.